Next Article in Journal
Early and Interdisciplinary Physiotherapy in a Patient in the Intensive Care Unit with a Bronchopulmonary Fistula after Thoracic Fenestration: A Case Report
Previous Article in Journal
Bronchoscopic Lung Volume Reduction Using Coil Therapy: Complications and Management
 
 
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Short-Acting Inhaled β2-Agonists: Why, Whom, What, How?

by
Andrzej Emeryk
1,* and
Justyna Emeryk-Maksymiuk
2
1
Department of Pediatric Pulmonology and Rheumatology Medical University in Lublin, Poland
2
Chair of Internal Medicine and Department of Internal Medicine in Nursing Medical University in Lublin, Poland
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2020, 88(5), 443-449; https://doi.org/10.5603/ARM.a2020.0132
Submission received: 24 May 2020 / Revised: 1 August 2020 / Accepted: 1 August 2020 / Published: 30 October 2020

Abstract

We showed the present data about the efficacy and safety of inhaled short-acting β2-agonists (SABA), such as salbutamol and fenoterol, in the management of obstructive diseases in children and adults. Our work discusses major mechanisms of action, clinical effects, possible side effects and indications of inhaled SABA. We presented current recommendations for the position of SABA in the therapy of obstructive diseases in children and adults, particularly in asthma and chronic obstructive pulmonary disease.
Keywords: short-acting β2-agonist; salbutamol; fenoterol; inhalation; nebulization; asthma; COPD short-acting β2-agonist; salbutamol; fenoterol; inhalation; nebulization; asthma; COPD

Share and Cite

MDPI and ACS Style

Emeryk, A.; Emeryk-Maksymiuk, J. Short-Acting Inhaled β2-Agonists: Why, Whom, What, How? Adv. Respir. Med. 2020, 88, 443-449. https://doi.org/10.5603/ARM.a2020.0132

AMA Style

Emeryk A, Emeryk-Maksymiuk J. Short-Acting Inhaled β2-Agonists: Why, Whom, What, How? Advances in Respiratory Medicine. 2020; 88(5):443-449. https://doi.org/10.5603/ARM.a2020.0132

Chicago/Turabian Style

Emeryk, Andrzej, and Justyna Emeryk-Maksymiuk. 2020. "Short-Acting Inhaled β2-Agonists: Why, Whom, What, How?" Advances in Respiratory Medicine 88, no. 5: 443-449. https://doi.org/10.5603/ARM.a2020.0132

Article Metrics

Back to TopTop